Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-21
DOI
10.1007/s00432-019-03086-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma
- (2019) Daniel Felix Fleischmann et al. RADIOTHERAPY AND ONCOLOGY
- Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
- (2018) D Gramatzki et al. ANNALS OF ONCOLOGY
- Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma
- (2017) Jennifer Clarke et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009
- (2016) Dorothee Gramatzki et al. CANCER
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option
- (2014) Maya Flieger et al. JOURNAL OF NEURO-ONCOLOGY
- Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma
- (2014) Mohamed A. Hamza et al. JOURNAL OF NEURO-ONCOLOGY
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
- (2014) David E. Piccioni et al. NEURO-ONCOLOGY
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
- (2013) Thomas Hundsberger et al. JOURNAL OF NEURO-ONCOLOGY
- Glioblastoma survival in the United States before and during the temozolomide era
- (2011) Derek R. Johnson et al. JOURNAL OF NEURO-ONCOLOGY
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started